Dean Falb
43Patents
12h-index
18Co-inventors
78Inventor score
Filing activity: Feb 10, 1995 → Jan 26, 2022
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6124433A | Compositions and methods for treatment and diagnosis of cardiovascular disease | Human Necessities | 103 | Expired |
| US6156500A | Methods for the treatment and diagnosis of cardiovascular disease | Human Necessities | 84 | Expired |
| US5948639A | TGF-.beta. pathway genes | Human Necessities | 40 | Expired |
| US6099823A | Compositions and methods for the treatment and diagnosis of cardiovascular disease | Chemistry; Metallurgy | 35 | Expired |
| US6048709A | Compositions and methods for the treatment and diagnosis of cardiovascular disease | Chemistry; Metallurgy | 27 | Expired |
| US9688967B2 | Bacteria engineered to treat diseases associated with hyperammonemia | Chemistry; Metallurgy | 26 | Active |
| US9487764B2 | Bacteria engineered to treat diseases associated with hyperammonemia | Emerging Cross-Sectional Technologies | 21 | Active |
| US6225084A | Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd534 as a target | Human Necessities | 19 | Expired |
| US9889164B2 | Bacteria engineered to treat a disease or disorder | Emerging Cross-Sectional Technologies | 18 | Active |
| US6087477A | Compositions and methods for the treatment and diagnosis of cardiovascular disease | Chemistry; Metallurgy | 17 | Expired |
| US10273489B2 | Bacteria engineered to treat diseases that benefit from reduced gut inflammation and/or tightened gut mucosal barrier | Emerging Cross-Sectional Technologies | 12 | Active |
| US5834248A | Compositions and methods using rchd534, a gene uregulated by shear stress | Human Necessities | 12 | Expired |
| US5807708A | Conservin nucleic acid molecules and compositions | Chemistry; Metallurgy | 11 | Expired |
| US6534641B2 | Compositions and methods for the treatment and diagnosis of cardiovascular disease | Chemistry; Metallurgy | 8 | Expired |
| US10933102B2 | Bacteria engineered to treat a disease or disorder | Emerging Cross-Sectional Technologies | 7 | Active |
| US5882925A | Compositions and method for the treatment and diagnosis of cardiovascular disease using rchd502 as a target | Human Necessities | 7 | Expired |
| US11291693B2 | Bacteria engineered to treat metabolic diseases | Emerging Cross-Sectional Technologies | 6 | Active |
| US11471494B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | Emerging Cross-Sectional Technologies | 6 | Active |
| US5849578A | Compositions and methods for the treatment and diagnosis of cardiovascular using RCHD528 as a target | Human Necessities | 5 | Expired |
| US11060073B2 | Bacteria engineered to treat diseases associated with hyperammonemia | Chemistry; Metallurgy | 4 | Active |
| US10610546B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 4 | Active |
| US11723932B2 | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | Chemistry; Metallurgy | 4 | Active |
| US9943555B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 4 | Active |
| US10195234B2 | Bacteria engineered to reduce hyperphenylalaninemia | Emerging Cross-Sectional Technologies | 4 | Active |
| US6018025A | Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target | Human Necessities | 3 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.